Paris Abstracts tamoxifen from a German health service perspective. METHODS: A semi-Markov model was adapted to include the 100-month clinical trial efficacy data. Kaplan-Meier curves on time to recurrence (TTR) from the ATAC trial were fitted by survival regression including a treatment coefficient. Treatment specific progression rates were extrapolated to 10 years, and were assumed equivalent based on pooled treatment arms thereafter. Survival probabilities after recurrence were identical for all treatments, based on German national mortality data. Published literature and physician survey provided data on resource use and unit costs and utilities. Probabilistic analysis was carried out to obtain incremental cost-effectiveness ratios and cost-effectiveness acceptability curves. Sensitivity analyses were conducted. RESULTS: Over 25 years anastrozole patients gained 0.32 QALYs at a cost of a6,819 per patient, resulting in an ICER of a21,069 (95%CI: a12,567-a46,604) per QALY gained, vs tamoxifen. With a 90% probability the ICER was below a30,000/QALY. The results were robust to plausible changes in parameters tested in sensitivity analyses, including the hazard ratio for TTR. CONCLUSIONS: This is the first cost-utility analysis of an aromatase inhibitor based on extended follow-up data. Anastrozole's carryover treatment effect beyond therapy completion at 5 years translates into favourable cost-effectiveness results against tamoxifen for PM HR EBC women from a German national health insurance perspective. OBJECTIVES: To evaluate cost-utility of docetaxel (75 mg/m 2 every 3 weeks) compared with best supportive care (BSC) or pemetrexed (500 mg/m 2 every 3 weeks) as second-line therapy in advanced non-small cell lung cancer in the Polish setting. METHODS: A cost-utility approach was adopted, evaluating total direct costs incurred by the Polish National Health Fund (NHF), life years gained (LYG) and quality-adjusted life years (QALY). A micro-simulation Markov model was used to estimate utilities and costs of treatment. The first course of chemotherapy was assumed as the starting-time point of the model. Simulation was terminated at the time of the patient's death or after two years following start of the treatment. It was assumed that patients would undergo 4 cycles of chemotherapy or less if progression occurred during treatment. In case of progression of disease chemotherapy would be terminated and patients would receive palliative care until death. Transition probabilities between health states were calculated based on a systematic review of RCTs. Health states utilities were taken from published literature. Costs were taken from NHF catalogue. Probabilistic sensitivity analysis was performed in order to estimate the probability that docetaxel was cost effective in Polish settings where threshold is about 91,000 polish zloty (PLN). RESULTS: Incremental costs for docetaxel compared with BSC was PLN57,498 per LYG and PLN105,956 per QALY. In 2-years time horizon docetaxel was PLN13,582 less costly than pemetrexed (CI95%: 8,224; 17,704). The probability of docetaxel cost effectiveness over BSC was 99.71% for LYG and 10.11% for QALY. The probability of docetaxel cost effectiveness over pemetrexed was 99.78% for LYG and 100% for QALY. CONCLUSIONS: Docetaxel seems to be cost effective in comparison with BSC and pemetrexed in the Polish setting.
1 National Cancer Registry of Ireland, Cork, Ireland, 2 National Centre for Pharmacoeconomics, Dublin, Ireland, 3 School for Health and Related Research (ScHARR), Sheffield, UK, 4 Trinity College Dublin, Dublin, Ireland, 5 Dublin City University, Dublin, Ireland OBJECTIVES: More than one million new cases of colorectal cancer are diagnosed worldwide annually. In Ireland, incidence rates are among the highest in western Europe, survival is lower than the European average, and mortality in men exceeds that in other western European countries. We evaluated the cost-effectiveness of a population-based colorectal cancer screening programme in Ireland. METHODS: Three screening scenarios were assessed: 1) biennial guaiac-based faecal occult blood testing (gFOBT) in those aged 55-74; 2) biennial faecal immunochemical testing (FIT) in those aged 55-74; and 3) once-only flexible sigmoidoscopy (FSIG) at age 60. A Markov model was used to followed a cohort of 55-year-old individuals over their lifetime. Model parameters were obtained from local data, literature review and expert clinical opinion. Costs included screening and diagnostic tests, cancer treatment, complications, and surveillance of screen-detected adenomas. Health outcomes were assessed in quality-adjusted life years (QALYs). Costs and outcomes were discounted at 4% per annum. Screening scenarios were compared with the status quo ("no screening"). Probabilistic sensitivity analyses were undertaken. RESULTS: All three screening scenarios were highly cost-effective compared to no screening. In the base-case analysis, FSIG had the lowest incremental cost-effectiveness ratio (ICER a589 per QALY gained), followed by FIT (a1,696 per QALY gained), and gFOBT (a4428 per QALY gained). gFOBT was dominated. Compared to FSIG, FIT was associated with a greater health gain, and greater lifetime reductions in colorectal cancer incidence (15%) and mortality (36%). However, it was more costly than FSIG, required more colonoscopies, and would result in more complications. The ICER for FIT versus FSIG was a2058 per QALY gained. Results were robust to variations in parameter estimates. CONCLUSIONS: These results suggest that population-based colorectal cancer screening would be a highly cost-effective in Ireland. FIT is the optimal screening strategy since it as associated with the greatest health gain.
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COST-EFFECTIVENESS ANALYSIS OF HORMONAL THERAPIES IN PATIENTS WITH ADVANCED PROSTATE CANCER IN ITALY
Iannazzo S 1 , Pradelli L 1 , Perachino M 2 1 AdRes HE&OR, Torino, Italy, 2 Ospedale S. Spirito, Casale Monferrato (AL), Italy OBJECTIVES: Prostatic cancer is the second most frequent cancer and the third highest cause of cancer-related deaths in Italy. Age is the principal risk factor and given the ageing Italian population, it seems that the related health care expenditure is bound to increase, causing the need for pharmacoeconomic evaluation of therapies available. METHODS: We performed a cost/utility analysis using a Markov model of hormonal therapies in patients with advanced prostate cancer who underwent radical prostatectomy, from biochemical recurrence to death. Nine androgen suppression therapies were considered: orchiectomy, two nonsteroidal antiandrogens (NSAA), four luteinising hormone-releasing hormone (LHRH) agonists, cyproterone acetate and the maximal androgen blockade (MAB) obtained with the association of a NSAA and a LHRH. In the simulation, the androgen suppression therapies were started at PSA recurrence and continued until death. The model used the Italian NHS prospective and a patient's lifetime simulation horizon. Drug costs were calculated for each therapy, considering the less costly brand. RESULTS: All therapies produced a life expectancy (LE) of about 12 life years (LYs) with a small variability ranging from 12.3 LYs for MAB to 11.37 LYs for NSAA-flutamide. Quality adjusted life expectancy ranged from 9.98 QALYs for MAB to 9.28 QALYs for NSAA-flutamide. The cost per patient presented more variability, from a12,538 for orchiectomy to a59,496 for NSAA-bicalutamide. Orchiectomy provided the most cost/effective alternative with a1300/QALY. In the LHRH-agonists class leuprorelin was the most cost/effective at about a2200/QALY. CONCLUSIONS: MAB was identified as the most effective and the most costly therapy. Orchiectomy was less effective but involved the lowest cost and, thus, represented the most cost/effective strategy. Nonetheless, its application in actual clinical practice is difficult and it is almost always refused by patients. Among the class of LHRH-agonists, leuprorelin (22.5 mg-7.5 mg) dominated the alternatives and provided an excellent therapeutic strategy.
